Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01081951|
Recruitment Status : Active, not recruiting
First Posted : March 5, 2010
Results First Posted : December 10, 2012
Last Update Posted : February 26, 2019
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Drug: olaparib Drug: paclitaxel Drug: carboplatin Drug: Drug: carboplatin||Phase 2|
Expanded Access : An investigational treatment associated with this study has been approved for sale to the public. More info ...
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||162 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer|
|Actual Study Start Date :||February 4, 2010|
|Actual Primary Completion Date :||October 10, 2011|
|Estimated Study Completion Date :||December 31, 2019|
200mg, 400mg BID - CAPSULES Olaparib paclitaxel iv and carboplatin iv
Oral dose capsule 200mg BID day 1-10 of every 21 day cycle, Oral dose capsule 400mg BID continuously after completion of combination therapy
175mg/m2 iv for up to 6 cycles (18 weeks)
Drug: Drug: carboplatin
AUC4 iv for up to 6 cycles (18 weeks)
Active Comparator: 2
paclitaxel iv and carboplatin iv
175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
Other Name: Taxol
AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
- Progression Free Survival (PFS) [ Time Frame: Radiologic scans performed at weeks 9 and 18 (+/-1 week) and every 12 weeks thereafter relative to the date of randomisation until the primary analysis (approximately 20 months) ]PFS (based on independent central review) was defined as the time from randomisation until objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 (≥20% increase in the sum of the diameters of target lesions from minimum, clinically significant progression in non-target lesions or the presence of a new lesion) or death (by any cause in the absence of progression).
- Overall Survival (OS) [ Time Frame: Following disease progression, patients will be contacted every 12 weeks to assess survival status until the final analysis (approximately 50 months) ]OS was defined as the time from randomisation until death by any cause. Patients who had not died at the time of analysis were censored at the last date the patient was known to be alive.
- Percentage Change in Tumour Size [ Time Frame: Week 9 (+/- 1 week) ]The total tumour size was defined as the sum of the longest diameters of the target lesions. At week 9, the percentage change in tumour size was calculated as [(week 9 sum of target lesions - baseline sum of target lesions)/baseline sum of target lesions]*100 for each patient. Imputations were used for missing data where possible.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01081951
Show 45 Study Locations
|Study Director:||Jane Robertson, BSc, MBCHB, MD||AstraZeneca|
|Principal Investigator:||Amit Oza, MD||Princess Margaret Hospital, Canada|